A brief review of kidney development, maturation, developmental abnormalities, and drug toxicity: juvenile animal relevancy
- PMID: 28458450
- PMCID: PMC5406591
- DOI: 10.1293/tox.2017-0006
A brief review of kidney development, maturation, developmental abnormalities, and drug toxicity: juvenile animal relevancy
Abstract
Nonclinical juvenile animal tests perform a valuable role in determining adverse drug effects during periods of organogenesis and/or functional maturation. Developmental anatomic and functional maturation time points are important to consider between juveniles and adults when regarding different organ toxicities in response to drug administration. The kidney is an example of a major organ that has differences in these time points in comparing juveniles to adults and in contrasting humans to laboratory animal species. Toxicologic pathologists, involved in juvenile studies, need to be aware of these time points which are age-related exposure periods of sensitivity to drug toxicity. Age-related developmental anatomic and functional maturation are factors which can affect the way that a drug is absorbed, distributed, metabolized, and excreted (ADME). Changes to any component of ADME may alter drug toxicity resulting in kidney abnormalities, nephrotoxicity, or maturational disorders. Juvenile animal kidneys may either be less resistant or more resistant to known adult nephrotoxic drug effects. Furthermore, drug toxicity observed in juvenile animal kidneys may not always correspond to similar toxicities in humans. Juvenile animal nonclinical toxicology studies targeting the kidneys have to be carefully planned to attain the maximum knowledge from each study.
Keywords: abnormalities; development; juvenile animals; kidney; maturation; toxicity.
Figures
References
-
- Beck MJ, Padgett EL, Bowman CJ, Wilson DT, Kaufman LE, Varsho BJ, Stump DG, Nemec MD, and Holson JF. Nonclinical juvenile toxicity testing. In: Developmental and Reproductive Toxicology, 2nd ed. RD Hood (ed). Taylor and Francis, Boca Raton. 263–327. 2006.
-
- Food and Drug Administration (FDA) Guidance for Industry Nonclinical Safety Evaluation of Pediatric Drug Products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Rockville. 2006.
-
- Osterberg RE. FDA Approach to pediatric testing. In: Pediatric Non-clinical Drug Testing: Principles, Requirements, and Practices. AM Hoberman, and EM Lewis (eds). John Wiley & Sons, Inc., Hoboken. 59–77. 2012.
-
- Lewis EM, De Schaepdrijver LM, and Coogan TP. Introduction. In: Pediatric Non-clinical Drug Testing: Principles, Requirements, and Practices. AM Hoberman, and EM Lewis (eds). John Wiley & Sons, Inc., Hoboken. 1–27. 2012.
-
- Bruckner JV. Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. Regul Toxicol Pharmacol. 31: 280–285. 2000. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources